Affitech and IBC Generium enter into a technology transfer agreement for the MBASTM technology

Affitech A/S, the antibody medicines company, announced that International Biotech Center Generium (IBC Generium) and Affitech Research AS, have entered into an agreement for the transfer of Molecular Based Antibody Screening (MBASTM) technology to IBC Generium. This new agreement strengthens the collaboration between the companies and provides to IBC Generium access to parts of Affitech’s antibody technology platform. The agreement includes the transfer of MBASTM technology as well as the access to Affitech’s phage antibody libraries.

As part of the agreement, Affitech will receive an up-front payment upon signature, a payment upon successful transfer of the technology and annual license fees. If products are isolated using the MBASTM technology platform, Affitech will be entitled to receive milestone payments and royalties. Under this agreement, Affitech expects to obtain revenues of 0.5 million euros in 2012.

For more information, please contact:
Randi Krogsgaard
Director IR & Corporate Communications
Tel: +45 2320 1001
E-mail: ir@affitech.com